Corcept Therapeutics Incorporated (CORT)
| Market Cap | 3.35B |
| Revenue (ttm) | 450.03M |
| Net Income (ttm) | 90.87M |
| Shares Out | 103.08M |
| EPS (ttm) | 0.81 |
| PE Ratio | 40.10 |
| Forward PE | 32.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 949,026 |
| Open | 32.87 |
| Previous Close | 32.88 |
| Day's Range | 32.43 - 33.07 |
| 52-Week Range | 17.86 - 34.28 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 31.00 (-4.56%) |
| Earnings Date | Feb 27, 2024 |
About CORT
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat pati... [Read more]
Financial Performance
In 2022, CORT's revenue was $401.86 million, an increase of 9.80% compared to the previous year's $365.98 million. Earnings were $101.29 million, a decrease of -9.98%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is $31.0, which is a decrease of -4.56% from the latest price.
News
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Appoints Monica Tellado as President, Emerging Markets
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
MENLO PARK, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on ...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on...
Corcept's Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
MENLO PARK, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sever...
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on...
Corcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sev...
Corcept Therapeutics Initiates CATALYST Clinical Trial
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat sev...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
MENLO PARK, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a ...
Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
New York, New York--(Newsfile Corp. - January 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
NEW YORK , Dec. 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therape...
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorpo...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporate...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporate...
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More - Corcept Therapeutics (NASDAQ:CORT), Cytek Biosciences (NASDAQ:CTKB)
The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat seve...
Corcept Investor Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclita...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Corcept Therapeutics Incorporated
Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) on...